AI Agent Evaluation in Production: Why Benchmarks Fail and What Enterprises Use

AI agent evaluation in production: benchmark scores versus enterprise results

AI agent evaluation has become the bottleneck for production teams. The top AI coding agent on SWE-bench currently resolves 87.6% of real GitHub software issues in a controlled evaluation. The top web-navigation agent on WebArena succeeds at 68.7% of browser tasks across realistic replications of Reddit, GitLab, and Shopify. These are genuine benchmark achievements — … Read more

The NextWave Signal — Issue #8 (Week of 24–30 May 2026)

NextWave Signal weekly briefing Issue #8 cover image

The NextWave SignalWeek of 24–30 May 2026 | Issue #8 Five articles this week, one through-line: the cost of deploying AI in production is getting harder to ignore. The EU sets a compliance clock. A semiconductor duopoly constrains supply. Open-weight models undercut closed APIs by 94%. WEEKLY SIGNAL METRIC $4.2B Hyper-Capex Spread Weekly capital expenditure … Read more

AI Economics in 2026: What DeepSeek, Llama, and Gemma Actually Cost Compared to OpenAI and Anthropic

AI economics cost per quality comparison across leading frontier models in 2026

The core AI economics cost per quality question for enterprise teams in 2026 is not which model is best — it is which model is best for a given price. That distinction matters because the benchmark gap between the cheapest open-weight models and the most expensive closed APIs has collapsed to a few percentage points, … Read more

HBM4 Ramp: Why Three Suppliers Still Add Up to a Duopoly for Nvidia

HBM4 ramp Nvidia

The HBM4 ramp Nvidia relies on is underway, with all three memory suppliers in volume production and Nvidia’s 2026 contract allocations already locked in. The headline — SK Hynix, Samsung, and Micron are all shipping next-generation High Bandwidth Memory (HBM) — suggests a more competitive supply chain than the HBM3E era produced. The reality is … Read more

The NextWave Signal — Issue #7 (Week of 17–23 May 2026)

NextWave Signal briefing Issue 7 weekly technology intelligence report

The NextWave SignalWeek of 17–23 May 2026 | Issue #7 — Executive NextWave Signal briefing Three articles this week, three verification tests. IBM needs independent researchers to confirm its quantum chemistry result. Rentosertib needs Phase III to replicate a 12-week signal in 500+ patients. Personalized mRNA cancer vaccines need regulators and payers to accept five-year … Read more

Nuclear Deals and Gigawatt Clusters: The 2026 AI Infrastructure Power Map

AI power infrastructure illustration showing nuclear deals and gigawatt-scale compute clusters

Nuclear Deals and Gigawatt Clusters: The 2026 AI Infrastructure Power Map — The crisis framing is over. Three nuclear plants. Four hyperscalers. A combined 10 gigawatts of power contracted in 18 months — extending our earlier reporting on grid stress precipitated by AI data centers and hyperscaler infrastructure capex financing. Twelve months ago, documented by … Read more

Inference-Time Compute in 2026: The Cost-Per-Answer Spread That Rewrote Production Economics

Inference-time compute economics and reasoning token costs across 2026 frontier models

The question engineering teams are now asking is not whether reasoning models work — they do — but whether the cost of inference-time compute is justified for their specific tasks. The answer is task-class-specific, and the spread is large. A benchmark study published in April 2026 measured cost-per-correct-answer across five frontier models on 900 math, … Read more

mRNA Cancer Vaccines Have Proven 5-Year Efficacy Data: Regulatory Submissions in 2026

mRNA cancer vaccines Phase 3 clinical data and regulatory submission timeline

Five years of follow-up on mRNA cancer vaccines. The same hazard ratio as year three. That is the signal that matters most in the latest data from the Moderna/Merck personalized mRNA cancer vaccine program — not because the number is exceptional, but because it has not moved. A benefit that holds its magnitude over five … Read more

The First End-to-End AI-Designed Drug Has Phase 2 Data. What Rentosertib’s Results Mean for the Pipeline.

AI-designed drug phase 2

This analysis looks at the latest AI-designed drug phase 2 evidence and what it means for development timelines. A 118.7 mL separation in forced vital capacity between treatment and placebo. Twelve weeks. Seventy-one patients. That is the data point the AI drug discovery field has been waiting for, and it arrived in June 2025 when … Read more

IBM Is Targeting Verified Quantum Advantage by Year-End 2026. Here Is What the Claim Actually Means.

IBM quantum advantage Nighthawk processor benchmarks and error mitigation 2026

The question behind every IBM quantum advantage claim is simple: does the machine beat classical computers on work that matters? Any claim of IBM quantum advantage should be tested against classical benchmarks that keep improving over time. Readers following IBM quantum advantage claims should separate peer-reviewed results from roadmap announcements. The practical test for IBM … Read more